Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response

Results of a preliminary study

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). Methods: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-Åsberg Depression Rating Scale at baseline (V1) and after a 4-week treatment period (V2). Patients with less than a 50% improvement in MADRS total scores during this period were regarded as non-responders. Results: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference - as a weak trend - was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). Limitations: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. Conclusions: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.

Original languageEnglish
Pages (from-to)269-273
Number of pages5
JournalJournal of Affective Disorders
Volume144
Issue number3
DOIs
Publication statusPublished - Jan 25 2013

Fingerprint

Vascular Endothelial Growth Factor A
Antidepressive Agents
Depression
Therapeutics
Mood Disorders
Nijmegen Breakage Syndrome
Bipolar Disorder
Sample Size
Nervous System
Biomarkers
Regression Analysis

Keywords

  • Bipolar disorder
  • Major depressive disorder
  • Treatment resistance
  • Treatment response
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

@article{9528d939aa304c51b0996158f5a16597,
title = "Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: Results of a preliminary study",
abstract = "Background: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). Methods: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-{\AA}sberg Depression Rating Scale at baseline (V1) and after a 4-week treatment period (V2). Patients with less than a 50{\%} improvement in MADRS total scores during this period were regarded as non-responders. Results: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference - as a weak trend - was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). Limitations: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. Conclusions: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.",
keywords = "Bipolar disorder, Major depressive disorder, Treatment resistance, Treatment response, Vascular endothelial growth factor",
author = "Zsuzsa Halmai and P. D{\"o}me and J. Dobos and X. Gonda and A. Sz{\'e}kely and M. Sasv{\'a}ri and G. Faludi and J. Laz{\'a}ry",
year = "2013",
month = "1",
day = "25",
doi = "10.1016/j.jad.2012.09.006",
language = "English",
volume = "144",
pages = "269--273",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response

T2 - Results of a preliminary study

AU - Halmai, Zsuzsa

AU - Döme, P.

AU - Dobos, J.

AU - Gonda, X.

AU - Székely, A.

AU - Sasvári, M.

AU - Faludi, G.

AU - Lazáry, J.

PY - 2013/1/25

Y1 - 2013/1/25

N2 - Background: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). Methods: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-Åsberg Depression Rating Scale at baseline (V1) and after a 4-week treatment period (V2). Patients with less than a 50% improvement in MADRS total scores during this period were regarded as non-responders. Results: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference - as a weak trend - was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). Limitations: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. Conclusions: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.

AB - Background: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). Methods: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-Åsberg Depression Rating Scale at baseline (V1) and after a 4-week treatment period (V2). Patients with less than a 50% improvement in MADRS total scores during this period were regarded as non-responders. Results: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference - as a weak trend - was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). Limitations: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. Conclusions: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.

KW - Bipolar disorder

KW - Major depressive disorder

KW - Treatment resistance

KW - Treatment response

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84870538332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870538332&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2012.09.006

DO - 10.1016/j.jad.2012.09.006

M3 - Article

VL - 144

SP - 269

EP - 273

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -